Drug Trial Radar · NCT02434328
Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,048
Actual
Start
Jul 28, 2015
Primary completion
Apr 5, 2017
Study completion Mar 8, 2018
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- May 5, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection (6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
Conditions
- Neovascular Age-Related Macular Degeneration
- Choroidal Neovascularization
Interventions
Brolucizumab ophthalmic solutionDrug
Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
Aflibercept ophthalmic solutionDrug
Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study EyeTime frame: Baseline, Week 48
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.